{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:40:49Z","timestamp":1793252449209,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Concomitant therapy (CT) and bismuth quadruple therapy (BQT) are recommended in geographical areas with high clarithromycin resistance for Helicobacter pylori (H. pylori) eradication. We compared CT and BQT as the first lines of treatment in a randomized controlled trial. Consecutive patients with H. pylori diagnosed by concordance of both a urea breath test and histology were recruited. For BQT, patients received 3 PyleraTM capsules q.i.d.; for CT, 1000 mg of amoxicillin b.i.d, 500 mg of clarithromycin b.i.d and 500 mg of metronidazole b.i.d. As a proton pump inhibitor, 40 mg of pantoprazole b.i.d was administered. Both regimens lasted 10 days. In total, 46 patients received CT and 38 BQT. Both groups were comparable for age (p = 0.27) and sex (p = 0.36). We did not record any drop outs; therefore, the intention to treat and per protocol rates coincided. The most common symptoms were heartburn and post-prandial fullness, which were equally present in both groups. The success rate was 95.6% for CT and 100% for BQT (p = 0.56). Side effects were recorded in 23.9% and 31.6% of patients in the CT and BQT arms, respectively (p = 0.47). The most common ones were abdominal pain (8) and diarrhea (6). In conclusion, CT and BQT are equally effective in our area with high clarithromycin resistance, southern Italy, and showed comparable safety.<\/jats:p>","DOI":"10.3390\/antibiotics13040348","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T06:07:46Z","timestamp":1712729266000},"page":"348","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Concomitant and Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Southern Italy: Preliminary Data from a Randomized Clinical Trial"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7038-3287","authenticated-orcid":false,"given":"Giuseppe","family":"Losurdo","sequence":"first","affiliation":[{"name":"Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia Valeria","family":"Borraccino","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Aloisio","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-6072","authenticated-orcid":false,"given":"Francesco","family":"Russo","sequence":"additional","affiliation":[{"name":"Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Riezzo","sequence":"additional","affiliation":[{"name":"Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-8565","authenticated-orcid":false,"given":"Grazia","family":"Galeano","sequence":"additional","affiliation":[{"name":"Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS \u201cSaverio de Bellis\u201d, 70013 Castellana Grotte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pricci","sequence":"additional","affiliation":[{"name":"THD s.p.a., 42015 Correggio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Girardi","sequence":"additional","affiliation":[{"name":"THD s.p.a., 42015 Correggio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-9153","authenticated-orcid":false,"given":"Francesca","family":"Celiberto","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"},{"name":"Ph.D. Course in Organs and Tissues Transplantation and Cellular Therapies, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Iannone","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-5080","authenticated-orcid":false,"given":"Enzo","family":"Ierardi","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-1200","authenticated-orcid":false,"given":"Alfredo","family":"Di Leo","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.14309\/ajg.0000000000002600","article-title":"Effectiveness of Helicobacter pylori treatments according to antibiotic resistance","volume":"119","author":"Bujanda","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Aumpan, N., Issariyakulkarn, N., Mahachai, V., Graham, D., Yamaoka, Y., and Vilaichone, R.K. (2023). Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0294403"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e13006","DOI":"10.1111\/hel.13006","article-title":"Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children","volume":"28","author":"Kotilea","year":"2023","journal-title":"Helicobacter"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nestegard, O., Moayeri, B., Halvorsen, F.A., T\u00f8nnesen, T., S\u00f8rbye, S.W., Paulssen, E., Johnsen, K.M., Goll, R., Florholmen, J.R., and Melby, K.K. (2022). Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0265322"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Guo, Z., Tian, S., Wang, W., Zhang, Y., Li, J., and Lin, R. (2022). Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in Refractory Helicobacter pylori Infections. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.861626"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Losurdo, G., Giorgio, F., Pricci, M., Girardi, B., Russo, F., Riezzo, G., Martulli, M., Piazzolla, M., Cocomazzi, F., and Abbruzzi, F. (2020). Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. Antibiotics, 9.","DOI":"10.3390\/antibiotics9100723"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-144-2-200601170-00006","article-title":"Clarithromycin-resistant genotypes and eradication of Helicobacter pylori","volume":"144","author":"Margiotta","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.dld.2003.12.015","article-title":"The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: A prospective, randomised study","volume":"36","author":"Zullo","year":"2004","journal-title":"Dig. Liver Dis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.7754\/Clin.Lab.2023.230512","article-title":"Helicobacter pylori Empirical and Tailored Eradication Therapy and Factors Influencing Eradication Rate: A 4-Year Single-Center Study","volume":"69","author":"Kim","year":"2023","journal-title":"Clin. Lab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/jgh.15939","article-title":"7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence","volume":"37","author":"Jung","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kim, Y.I., Lee, J.Y., Kim, C.G., Park, B., Park, J.Y., and Choi, I.J. (2021). Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: A randomized open-label trial. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-021-01680-1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.dld.2022.06.019","article-title":"Management of Helicobacter pylori infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED)","volume":"54","author":"Romano","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ueg2.12348","article-title":"Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management","volume":"11","author":"Gatta","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.dld.2017.10.009","article-title":"Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: A prospective, randomized study","volume":"50","author":"Pontone","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.3748\/wjg.v25.i46.6790","article-title":"Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial","volume":"25","author":"Kim","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(16)31409-X","article-title":"Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial","volume":"388","author":"Liou","year":"2016","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/apt.13497","article-title":"Review article: The global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Jearth, V., Rath, M.M., Chatterjee, A., Kale, A., and Panigrahi, M.K. (2023). Drug-Resistant Helicobacter pylori: Diagnosis and Evidence-Based Approach. Diagnostics, 13.","DOI":"10.3390\/diagnostics13182944"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mladenova, I. (2023). Epidemiology of Helicobacter pylori Resistance to Antibiotics (A Narrative Review). Antibiotics, 12.","DOI":"10.3390\/antibiotics12071184"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Boyanova, L., Hadzhiyski, P., Gergova, R., and Markovska, R. (2023). Evolution of Helicobacter pylori Resistance to Antibiotics: A Topic of Increasing Concern. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020332"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Losurdo, G., Lacavalla, I., Russo, F., Riezzo, G., Brescia, I.V., Rendina, M., Ierardi, E., and Di Leo, A. (2022). Empiric \u201cThree-in-One\u201d Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. Antibiotics, 11.","DOI":"10.3390\/antibiotics11010078"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zagari, R.M., Dajti, E., Cominardi, A., Frazzoni, L., Fuccio, L., Eusebi, L.H., Vestito, A., Lisotti, A., Galloro, G., and Romano, M. (2023). Standard Bismuth Quadruple Therapy versus Concomitant Therapy for the First-Line Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093258"},{"key":"ref_25","first-page":"52","article-title":"Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial","volume":"16","author":"Kefeli","year":"2016","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4066\/biomedicalresearch.29-17-2840","article-title":"Comparison of the efficacy of six different Helicobacter pylori eradication regimens: Greater than or equal to another","volume":"29","author":"Sezikli","year":"2018","journal-title":"Biomed. Res."},{"key":"ref_27","first-page":"28","article-title":"The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori\u2014Associated gastric and duodenal peptic ulcer disease","volume":"91","author":"Veliev","year":"2019","journal-title":"Ter. Arkh."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1053\/j.gastro.2020.11.059","article-title":"AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review","volume":"160","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13099-023-00556-x","article-title":"A day-to-day management model improves patient compliance to treatment for Helicobacter pylori infection: A prospective, randomized controlled study","volume":"15","author":"Yang","year":"2023","journal-title":"Gut Pathog."},{"key":"ref_30","first-page":"467","article-title":"Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera) to eradicate Helicobacter pylori infection in 200 patients","volume":"111","year":"2019","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12664-018-0916-z","article-title":"Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial","volume":"37","author":"Shahbazi","year":"2018","journal-title":"Indian J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1756283X09337342","article-title":"Improving compliance with helicobacter pylori eradication therapy: When and how?","volume":"2","author":"Taneike","year":"2009","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10238-022-00953-7","article-title":"The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: A systematic review and meta-analysis","volume":"23","author":"Ding","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41395-018-0217-2","article-title":"Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection","volume":"113","author":"Chen","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102529","DOI":"10.1016\/j.eclinm.2024.102529","article-title":"10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: A randomised, open-label, non-inferiority trial","volume":"70","author":"Yang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","article-title":"Role of bismuth in improving Helicobacter pylori eradication with triple therapy","volume":"65","author":"Dore","year":"2016","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Marano, L., Verre, L., Carbone, L., Poto, G.E., Fusario, D., Venezia, D.F., Calomino, N., Ka\u017amierczak-Siedlecka, K., Polom, K., and Marrelli, D. (2023). Current Trends in Volume and Surgical Outcomes in Gastric Cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072708"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1053\/j.gastro.2021.05.045","article-title":"Helicobacter pylori Antibiotic Resistance: Stewardship, Tailored Therapies, and Future Perspectives","volume":"161","author":"Losurdo","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ueg2.12473","article-title":"The use of non-invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance","volume":"11","author":"Mommersteeg","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/1751-2980.13250","article-title":"Tailored therapy guided by genotypic resistance of clarithromycin and levofloxacin detected by polymerase chain reaction in the first-line treatment of Helicobacter pylori infection","volume":"25","author":"Li","year":"2024","journal-title":"J. Dig. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Schuetz, A.N., Theel, E.S., Cole, N.C., Rothstein, T.E., Gordy, G.G., and Patel, R. (2024). Testing for Helicobacter pylori in an era of antimicrobial resistance. J. Clin. Microbiol., 62.","DOI":"10.1128\/jcm.00732-23"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"17562848231196357","DOI":"10.1177\/17562848231196357","article-title":"Empirical versus tailored therapy based on genotypic resistance detection for Helicobacter pylori eradication: A systematic review and meta-analysis","volume":"16","author":"Li","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e13015","DOI":"10.1111\/hel.13015","article-title":"Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis","volume":"28","author":"Lin","year":"2023","journal-title":"Helicobacter"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e12522","DOI":"10.1111\/hel.12522","article-title":"Helicobacter pylori and nonmalignant upper gastrointestinal diseases","volume":"23","author":"Jonaitis","year":"2018","journal-title":"Helicobacter"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12664-021-01195-3","article-title":"Role of Helicobacter pylori eradication in patients with functional dyspepsia","volume":"40","author":"Padole","year":"2021","journal-title":"Indian J. Gastroenterol."},{"key":"ref_46","first-page":"382","article-title":"A prospective study on Helicobacter pylori rapid urease test false negativity: Is it time for its use in restricted situations?","volume":"69","author":"Losurdo","year":"2023","journal-title":"Minerva Gastroenterol. (Torino)"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2009.03951.x","article-title":"Methodology and indications of H2-breath testing in gastrointestinal diseases: The Rome Consensus Conference","volume":"29","author":"Gasbarrini","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_48","first-page":"51","article-title":"13C-Urea breath test for the diagnosis of Helicobacter pylori infection","volume":"17","author":"Ojetti","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/apt.12383","article-title":"Adherence to the Sydney System guidelines increases the detection of Helicobacter gastritis and intestinal metaplasia in 400738 sets of gastric biopsies","volume":"38","author":"Lash","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Latorre, G., Vargas, J.I., Shah, S.C., Ivanovic-Zuvic, D., Achurra, P., Fritzsche, M., Leung, J.S., Ramos, B., Jensen, E., and Uribe, J. (2023). Implementation of the updated Sydney system biopsy protocol improves the diagnostic yield of gastric preneoplastic conditions: Results from a real-world study. Gastroenterol. Hepatol., S0210-5705(23)00391-6.","DOI":"10.1016\/j.gastrohep.2023.08.005"},{"key":"ref_51","first-page":"1488","article-title":"Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction","volume":"71","author":"Sugano","year":"2022","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/4\/348\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:25:30Z","timestamp":1760106330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/4\/348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["antibiotics13040348"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13040348","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]}}}